Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 20, 2017. The document serves as a transaction notification regarding a purchase of company securities by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is a regulatory disclosure of a specific securities transaction.
| Transaction Type | Instrument | Volume | Price |
|---|---|---|---|
| Acquisition | American Depositary Shares (ADSs) | 25.454 | $41.1310 |
Material Changes
The filing reports an acquisition of 25.454 ADSs by Mr. B McNamara, CEO of Consumer Healthcare. This transaction occurred on October 19, 2017, on the New York Stock Exchange. The purchase was executed following the re-investment of dividends paid to shareholders on October 12, 2017, under the Deferred Annual Bonus Plan Post-Tax.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risks, contingencies, or unusual items. The document is strictly a notification of a PDMR transaction.
Key Facts for Investor Verification
- The transaction involved the acquisition of ADSs by a senior executive (CEO, Consumer Healthcare) via a dividend reinvestment plan.
- The transaction price was $41.1310 per ADS.
- The filing does not disclose any changes to the company's financial position or strategic outlook.
- Investors should verify the total holdings of the executive post-transaction in subsequent filings if required for compliance analysis.